News

Researchers from Ghent University have published a study that has the potential to transform inherited retinal disease (IRD) treatment development.

Researchers from the University Hospital Tübingen in Germany recently announced that there were no signs of visual gains in an early-phase clinical trial of a PDE6A gene therapy for Retinitis Pigmentosa (RP).

It has recently been announced that Meira-GTx, who originally developed bota-vec and collaborated with J&J during its early clinical trials, have entered into an asset purchase agreement with J&J to acquire bota-vec and progress the program towards global regulatory filings for approval.

Researchers in the Netherlands are developing a “retina-on-a-chip” that mimics the key layers of the human retina, offering a powerful new way to study inherited retinal diseases (IRDs) and test potential treatments using human cells.

A recently published study has provided the first molecular map of the mutation-specific changes that occur in the retina which lead to Congenital Stationary Night Blindness.

SparingVision have announced this week that they have dosed all participants in their phase 1/2 PRODYGY clinical trial for SPVN06, a gene agnostic therapy aimed at slowing disease progression in Retinitis Pigmentosa (RP).

Please find below a research opportunity for people with confirmed stargardt disease.

Ocugen’s gene therapy candidate, OCU410ST, is an experimental treatment designed to slow vision loss in Stargardt disease, an inherited retinal disease (IRD) with no approved therapies currently.

SpliceBio has begun the dose-expansion portion of their phase 1/2 clinical trial of SB-007, a dual adeno-associated viral vector gene therapy for Stargardt disease.